StockStory Identifies Vertex, Clover Health as Buys; Cooper Companies Draws Caution

Healthcare stocks have trailed the broader market, but StockStory analysts on May 29, 2026 see upside in Vertex Pharmaceuticals (VRTX) and Clover Health (CLOV), while signaling caution on Cooper Companies (COO). The sector returned 4.1% over the past six months, lagging the S&P 500 by 6.2 percentage points as firms worked through surplus COVID-era inventories. Vertex, trading at $447.05 with a 22.3x forward price-to-earnings ratio, was cited for its portfolio of transformative medicines targeting disease causes. Clover Health, at $4.14 and 39.9x forward P/E, drew praise for its technology-driven Medicare Advantage approach. In contrast, Cooper Companies, priced at $61.02 with a 13x forward multiple, was highlighted as facing headwinds. The note did not provide specific earnings forecasts.